Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites

20 Jun 2015

Abstract excerpt

Histone deacetylase (HDAC) enzymes work together with histone acetyltransferases (HATs) to reversibly acetylate both histone and non-histone proteins. As a result, these enzymes are involved in regulating chromatin structure and gene expression as well as other important cellular processes. HDACs are validated drug targets for some types of cancer, with four HDAC inhibitors clinically approved. However, they are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26199860
DOI: 10.1016/j.ijpddr.2015.05.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasitesPMID 26199860Read ↗

Ex Vivo Activity of Histone Deacetylase Inhibitors against Multidrug-Resistant Clinical Isolates of Plasmodium falciparum and P. vivaxSemantic proximity Read ↗

Histone Deacetylases As Targets for Antitrypanosomal DrugsSemantic proximity Read ↗

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.Semantic proximity Read ↗

Targeting histone deacetyalses in the treatment of B- and T-cell malignanciesSemantic proximity Read ↗

Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasitesSemantic proximity Read ↗

Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase InhibitorsSemantic proximity Read ↗

Identification and Characterization of Small Molecule Inhibitors of a Class I Histone Deacetylase from <i>Plasmodium falciparum</i>Semantic proximity Read ↗

HDAC8: a multifaceted target for therapeutic interventions.Semantic proximity Read ↗

Genome‐wide survey and phylogenetic analysis of histone acetyltransferases and histone deacetylases of Plasmodium falciparumSemantic proximity Read ↗

Histone deacetylase inhibitors with high in vitro activities against Plasmodium falciparum isolates collected from Gabonese children and adults.Semantic proximity Read ↗

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsSemantic proximity Read ↗

Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.